Market Overview:
The global Eptifibatide market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of cardiovascular diseases, increasing awareness about early diagnosis and treatment of heart diseases, and technological advancements in the field of cardiology. The global Eptifibatide market is segmented on the basis of type, application, and region. On the basis of type, it is divided into 0.75mg/ml and 2mg/ml segments. On the basis of application, it is classified into unstable angina, myocardial infarction (MI), and other applications segments. Geographically, it is analyzed across North America (U.S., Canada), Latin America (Mexico Brazil), Europe (Germany France U.K.), Asia Pacific (China Japan India South Korea Australia Singapore Malaysia Indonesia Thailand Vietnam Philippines Pakistan Bangladesh Sri Lanka), Middle East & Africa (GCC Countries Israel South Africa Nigeria Kenya Tanzania Uganda).
Product Definition:
Eptifibatide is a drug used to prevent blood clots. It is given as an injection, usually into a vein in your arm.
0.75mg/ml:
0.75mg/ml is the concentration of Eptifibatide in water, it's used for preventing blood clotsting and to treat patients with chronic kidney disease, heart failure or coronary artery disease. It works by changing the shape of a certain protein present in blood cells which reduces their ability to form a clot.
2mg/ml:
2mg/ml is the concentration of Eptifibatide in the market. It is used as an active ingredient in various pharmaceutical products such as Aranesp and Vectibix. 2mg/ml is also known as Epi pro-drug, which means it’s a pro-drug for eptifibatide monohydrate 5 mg/ ml.
Application Insights:
Based on the application, the global eptifibatide market is segmented into Unstable Angina (UA), myocardial infarction (MI) and other applications. The other applications include heart valve problems, stroke and pulmonary embolism. The use of eptifibatide for treating these conditions has not been approved by the U.S FDA yet; therefore, it remains unestablished in North America and Europe. However, it is established in countries such as Japan, China and India due to adoption of biosimilars technology for treatment of cardiovascular diseases which are still under testing phase within the region.
Regional Analysis:
North America dominated the global eptifibatide market in 2017 with a revenue share of over 40.0%. This is attributed to favorable reimbursement policies, increasing incidence of cardiovascular diseases and growing awareness about early diagnosis. In addition, presence of key players in this region is expected to drive the growth further.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to improving healthcare infrastructure and rising patient awareness regarding CVD prevention strategies along with an increase in disposable income levels which will result into higher demand for expensive drugs such as eptifibatide 2mg/ml formulation.
Growth Factors:
- Increasing incidence of cardiovascular diseases (CVDs) across the globe is expected to drive the demand for Eptifibatide over the forecast period.
- Rising geriatric population is also anticipated to fuel market growth as this population is more susceptible to CVDs.
- Growing awareness about early diagnosis and treatment of CVDs will propel the demand for Eptifibatide in coming years.
- Technological advancements in drug delivery systems are likely to provide lucrative opportunities for market players over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Eptifibatide Market Research Report
By Type
0.75mg/ml, 2mg/ml
By Application
Unstable Angina, Myocardial Infarction, Other
By Companies
Merck, Taj Pharmaceuticals, Cigna, Gland Pharma, AuroMedics Pharma, Millennium Pharmaceuticals, Hybio Pharmaceutical, GlaxoSmithKline, Schering-Plough Corporation, Novetide
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Eptifibatide Market Report Segments:
The global Eptifibatide market is segmented on the basis of:
Types
0.75mg/ml, 2mg/ml
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Unstable Angina, Myocardial Infarction, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Taj Pharmaceuticals
- Cigna
- Gland Pharma
- AuroMedics Pharma
- Millennium Pharmaceuticals
- Hybio Pharmaceutical
- GlaxoSmithKline
- Schering-Plough Corporation
- Novetide
Highlights of The Eptifibatide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 0.75mg/ml
- 2mg/ml
- By Application:
- Unstable Angina
- Myocardial Infarction
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Eptifibatide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Eptifibatide is a medication used to prevent blood clots. It is also known by the brand name Tirofiban.
Some of the key players operating in the eptifibatide market are Merck, Taj Pharmaceuticals, Cigna, Gland Pharma, AuroMedics Pharma, Millennium Pharmaceuticals, Hybio Pharmaceutical, GlaxoSmithKline, Schering-Plough Corporation, Novetide.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Eptifibatide Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Eptifibatide Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Eptifibatide Market - Supply Chain
4.5. Global Eptifibatide Market Forecast
4.5.1. Eptifibatide Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Eptifibatide Market Size (000 Units) and Y-o-Y Growth
4.5.3. Eptifibatide Market Absolute $ Opportunity
5. Global Eptifibatide Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Eptifibatide Market Size and Volume Forecast by Type
5.3.1. 0.75mg/ml
5.3.2. 2mg/ml
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Eptifibatide Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Eptifibatide Market Size and Volume Forecast by Application
6.3.1. Unstable Angina
6.3.2. Myocardial Infarction
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Eptifibatide Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Eptifibatide Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Eptifibatide Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Eptifibatide Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Eptifibatide Demand Share Forecast, 2019-2026
9. North America Eptifibatide Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Eptifibatide Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Eptifibatide Market Size and Volume Forecast by Application
9.4.1. Unstable Angina
9.4.2. Myocardial Infarction
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Eptifibatide Market Size and Volume Forecast by Type
9.7.1. 0.75mg/ml
9.7.2. 2mg/ml
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Eptifibatide Demand Share Forecast, 2019-2026
10. Latin America Eptifibatide Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Eptifibatide Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Eptifibatide Market Size and Volume Forecast by Application
10.4.1. Unstable Angina
10.4.2. Myocardial Infarction
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Eptifibatide Market Size and Volume Forecast by Type
10.7.1. 0.75mg/ml
10.7.2. 2mg/ml
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Eptifibatide Demand Share Forecast, 2019-2026
11. Europe Eptifibatide Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Eptifibatide Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Eptifibatide Market Size and Volume Forecast by Application
11.4.1. Unstable Angina
11.4.2. Myocardial Infarction
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Eptifibatide Market Size and Volume Forecast by Type
11.7.1. 0.75mg/ml
11.7.2. 2mg/ml
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Eptifibatide Demand Share, 2019-2026
12. Asia Pacific Eptifibatide Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Eptifibatide Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Eptifibatide Market Size and Volume Forecast by Application
12.4.1. Unstable Angina
12.4.2. Myocardial Infarction
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Eptifibatide Market Size and Volume Forecast by Type
12.7.1. 0.75mg/ml
12.7.2. 2mg/ml
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Eptifibatide Demand Share, 2019-2026
13. Middle East & Africa Eptifibatide Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Eptifibatide Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Eptifibatide Market Size and Volume Forecast by Application
13.4.1. Unstable Angina
13.4.2. Myocardial Infarction
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Eptifibatide Market Size and Volume Forecast by Type
13.7.1. 0.75mg/ml
13.7.2. 2mg/ml
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Eptifibatide Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Eptifibatide Market: Market Share Analysis
14.2. Eptifibatide Distributors and Customers
14.3. Eptifibatide Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Taj Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Cigna
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Gland Pharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AuroMedics Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Millennium Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hybio Pharmaceutical
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GlaxoSmithKline
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Schering-Plough Corporation
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novetide
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook